Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial

The publication “Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial” is organized in H2HUBB under the research focus molecular hydrogen respiratory health study 2021 ze-guang. The publication is cited as Zheng Ze-Guang, Sun Wu-Zhuang, Hu Jie-Ying, Jie Zhi-Jun, Xu Jin-Fu, Cao Jie, Song Yuan-Lin, Wang Chang-Hui, Wang Jing, Zhao Hui, Guo Zhong-Liang, Zhong Nan-Shan, Respiratory Research, 2021. This registered clinical trial examined Hydrogen/oxygen therapy for the treatment of an acute exacerbation of chronic obstructive pulmonary disease: results of a multicenter, randomized, double-blind, parallel-group controlled trial. The abstract describes Planned or registered research population. The abstract reports: The trial demonstrated that hydrogen/oxygen therapy is superior to oxygen therapy in patient with AECOPD with acceptable safety and tolerability profile. This is an automated editorial draft based on the abstract and requires source review before publication.

Molecular hydrogen respiratory health study 2021 ze-guang overview

To investigate whether the administration of hydrogen/oxygen mixture was superior to oxygen in improving symptoms in patients with acute exacerbation of chronic obstructive pulmonary… A protocol describes planned methods and does not provide completed outcome evidence.

Study design and hydrogen intervention

Publication type: Registered clinical trial. Evidence type: Protocol or ongoing research. Research model or population: Planned or registered research population. Randomized: Yes. Blinding: Double-blind. Control status: Unknown.

Delivery method: Other or not reported.

Reported findings and scientific interpretation

For this molecular hydrogen respiratory health study 2021 ze-guang, the study record reports the following: The abstract reports: The trial demonstrated that hydrogen/oxygen therapy is superior to oxygen therapy in patient with AECOPD with acceptable safety and tolerability profile.

These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.

How this research record was prepared

H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.

Limitations, safety, and original source

Limitations: The abstract alone may not report all methodological limitations; full-text review is required.

Safety: Adverse events (AEs) were recorded to evaluate safety.

This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.